CTF along with NTAP and Sage announce first-ever open data portal for neurofibromatosis

NewsGuard 100/100 Score

The Children's Tumor Foundation (CTF), together with the Neurofibromatosis Therapeutic Acceleration Program (NTAP) and Sage Bionetworks (Sage), has announced the first-ever open data portal for scientific research results in the field of neurofibromatosis (NF). The NF Data Portal marks the major first milestone in all three organizations' commitment to the development of the larger NF Open Science Initiative (NF-OSI), which draws experts from across research disciplines and disease areas in order to develop treatments for NF, a genetic disorder which affects 2.5 million people worldwide (1 in 3,000 births), and currently has no cure or effective treatment options.

The unique challenge for researchers studying NF, and particularly for patients living with the disease, is that NF is extremely variable. It causes tumors to grow on nerves throughout the body, and can cause deafness, blindness, disfigurement, bone abnormalities, learning disabilities, disabling pain and cancer. This makes diagnosis and treatment particularly difficult, and as a result, many patients are told to 'watch and wait' as their tumors grow. Researchers working on the disease have likewise faced the challenge of working in independent groups and relying primarily on data made public through published works.

The Children's Tumor Foundation looked to turn this 'traditional research model' on its head, and in 2014 launched the NF Open Science Initiative, in collaboration with Sage Bionetworks, in order to enable CTF sponsored project teams to share their data in real-time through Sage Bionetworks' Synapse platform. This was started in connection with the Foundation's Synodos research model, which brings together multidisciplinary experts from leading institutions and across basic, translational and clinical disciplines, in order to solve complex NF issues.

This spirit of collaboration has attracted other significant partners, and in 2015, CTF committed to supporting data collection and integration from a large National Cancer Institute (NCI) project, called DHART SPORE (Developmental and HyperActive Ras Tumor Specialized Programs of Research Excellence). That same year, NTAP initiated a relationship with Sage requiring that data generated through NTAP funded initiatives be uploaded, harmonized and indexed within Synapse. Across all of these projects - from CTF to NTAP to the NCI - Sage Bionetworks interacts directly with the project scientists to coordinate data upload and organization, and applies expertise in computational biology, oncology, data harmonization, and community-building to expand and enhance the value of the data generated across all of these initiatives.

Building on the success of these efforts, CTF, NTAP and Sage have formally aligned to launch the NF Data Portal and the NF Open Science Initiative to support:

  • computational biologists seeking to analyze NF data and run their analyses,
  • bench scientists who are interested in seeing what models/studies have been carried out on NF-related models,
  • clinicians interested in seeing if a compound of interest has been used in an in-vivo, in-vitro or an in-silico model, and
  • the general public who are interested in reading about what symptoms of NF are currently being studied.

All content in the NF Data Portal is compatible with global scientific initiatives to establish common vocabularies and protocols for sharing data across all diseases. Furthermore, the NF Data Portal hosts analysis tools to integrate different modalities of data including drug efficacy across model systems, drug-target analysis, clinical trial data, and molecular adaptive responses in patients. The datasets coming from funded research are subject to a short embargo period (generally up to 18 months), during which the researchers will use the Data Portal for their own research before releasing the dataset to the research community under a Creative Commons (CC) license, or similar. The user-centered design approach employed by Sage Bionetworks for the NF Data Portal enables more users to easily find and access the data they need.

As the portal evolves and grows, it will include data from other significant research programs, such as the CDMRP-NF program (Congressionally Directed Medial Research Programs in Neurofibromatosis), as well as other funders of NF research. All are welcome to participate.

"We are very excited to have attracted the most important funders of NF research in order to enhance and expand use of the NF Data Portal, and to be working with Sage Bionetworks, which possesses the expertise to build what we consider to be the most promising model of data-sharing in the rare disease area," said Salvatore La Rosa, PhD, Chief Scientific Officer of the Children's Tumor Foundation.

Sara Gosline, PhD, Senior Scientist at Sage Bionetworks and lead of the NF Open Science Initiative, added, "Through our work with CTF and NTAP we have been able to capture an unprecedented amount of data across the NF community that will undoubtedly fuel further scientific discoveries in this field."

La Rosa concluded, "This is big news for researchers, but ultimately even bigger news for patients, who can be assured that critical information is being shared openly so that treatments can be developed as quickly as possible."

Source: https://www.ctf.org/news/open-science-and-data-initiative-announced-for-neurofibromatosis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts